In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ES Cell International Pte. Ltd.

Division of BioTime Inc.

Latest From ES Cell International Pte. Ltd.

Deals Shaping The Medical Industry, January 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2014.

BioPharmaceutical Medical Device

BioTime takes exclusive license on Cornell embryonic vascular stem cell technology

BioTime has entered into an exclusive licence agreement with Cornell University for the worldwide development and commercialisation of technology developed at Weill Cornell Medical College for the differentiation of human embryonic stem cells into vascular endothelial cells.

Metabolic Disorders Cancer

Deals Shaping the Medical Industry (06/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Market Insight - Stem cells: the unsteady rise of the East?

South Korea has had an unsteady early relationship with stem cell research and the country has yet to recover fully from the high-profile Hwang Woo-Suk cloning scandal of 2006. This South Korean scientist famously and fraudulently reported to have succeeded in creating human embryonic stem (hES) cells by nuclear transfer. The scandal received widespread coverage in the media and dealt a terrible blow to the country on the embryonic stem cell research stage. Yet, the hero status bestowed on Dr Hwang before his downfall indicated that Asian governments supported, and that their communities were ready for, stem cell therapies.

Metabolic Disorders Cardiovascular
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Southeast Asia
        • Singapore
  • Parent & Subsidiaries
  • BioTime Inc.
  • Senior Management
  • Michael D West, CEO
    Bruce Davidson, PhD, Gen. Mgr./CSO
  • Contact Info
  • ES Cell International Pte. Ltd.
    Phone: (65) 6774 9533
    60 Biopolis St.
    Genome, 138672